Severe Psoriasis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Psoriasis represents a chronic inflammatory skin condition characterized by erythematous plaques adorned with silvery scales commonly observed on extensor surfaces, the scalp, and the lumbosacral region. This disorder may also extend its impact on the joints and eyes. The underlying pathophysiology of psoriasis involves infiltrating activated T cells into the skin, stimulating keratinocyte proliferation. This dysregulated keratinocyte turnover mechanism culminates in the formation of thickened plaques. Phototherapy constitutes a standard treatment modality, encompassing PUVA therapy, which involves the combination of psoralen and exposure to ultraviolet light (UVA), along with Narrowband UVB (NBUVB) therapy, employing light within the range of 311 to 313 nanometers. Approximately 2% of the population in the United States suffers from psoriasis. The Psoriasis Area Severity Index (PASI) is the predominant tool for quantifying the severity of the condition, facilitating the assessment of treatment efficacy.
Thelansis’s “Severe Psoriasis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Severe Psoriasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Severe Psoriasis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Severe Psoriasis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment